Citadel Advisors’s IN8bio INAB Stock Holding History

Citadel Advisors’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-24,728	Closed	-$53.7K	–	13324
2025 Q3	$53.7K	Buy	+24,728	New	+$54.4K	﹤0.01%	12161
2025 Q2	–	Sell	-982	Closed	-$4.89K	–	13724
2025 Q1	$4.89K	Buy	+982	New	+$7.83K	﹤0.01%	13856
2024 Q1	–	Sell	-660	Closed	-$27.3K	–	14995
2023 Q4	$27.3K	Buy	+660	New	+$21.1K	﹤0.01%	12342
2023 Q3	–	Sell	-1,924	Closed	-$88.9K	–	14662
2023 Q2	$88.9K	Buy	+1,924	New	+$120K	﹤0.01%	11101

Other funds holding INAB

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's INAB Position: Q4 2025 in Review

Citadel Advisors sold out of IN8bio (INAB) in Q4 2025, closing a stake of 24,728 shares — an estimated $53.7K sold.

Citadel Advisors first reported a position in INAB in Q2 2023 and held it in 4 quarters. The position peaked at $88.9K in Q2 2023. 22 funds tracked by Wall St. Rank hold INAB as of Q4 2025.

Citadel Advisors reported no remaining IN8bio position as of Q4 2025 after selling out during the quarter.
Citadel Advisors sold 24,728 IN8bio shares in Q4 2025, an estimated $53.7K.
Citadel Advisors first reported a position in IN8bio in Q2 2023 and held it in 4 quarters.
Citadel Advisors's IN8bio position peaked at $88.9K in Q2 2023.
22 funds tracked by Wall St. Rank held IN8bio as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.